PBM Fraud Cases, Audits and Settlements: Different Claims, Different Outcomes

PBM fraud settlements and cases turn on what a company told a health plan or government program about drug costs, rebates or services. The prescription can reach the patient while a later report conceals the discount, moves the profit or charges for work nobody performed. If you work in pricing, rebate accounting, contracting or plan reporting, the discrepancy behind a case may look familiar long before the settlement headline does.

Caremark’s Medicare judgment followed pricing offsets between commercial and government business. Elixir’s settlement concerned rebates allegedly reported as service fees. California’s Centene settlement concerned costs reported to Medi-Cal.

How PBM Reporting Changes the Government’s Bill

A pharmacy benefit manager can influence government payments through the information it supplies to a health plan. The pharmacy submits its claim to a processor, the plan funds the benefit, and manufacturer rebates may arrive through a separate intermediary after dispensing. Pharmacy payments, manufacturer receipts and the plan’s final cost therefore sit in different records.

The Elixir agreement describes the reporting connection directly: Medicare Part D sponsors submit annual rebate and remuneration reports, and Medicare uses them to reconcile payments at year-end. The manufacturer agreement, rebate remittance, service-fee classification and sponsor report each tell part of that story. A person who understands how an amount moved between them can explain a discrepancy that a paid prescription alone will never show.

False Claims Act Cases Follow the Reported Price

Caremark’s Judgment Followed the Year-End Offsets

Caremark’s pricing case produced a $289,873,500 judgment on August 19, 2025. The court found that Caremark caused Aetna and SilverScript to misreport Medicare Part D drug costs at Walgreens and Rite Aid in 2013 and 2014. It assessed $95 million in government losses before tripling damages and adding civil penalties.

The mechanism sits in the court’s findings about the pharmacy contracts. Caremark promised pharmacies an average reimbursement rate across commercial and Part D purchases. Higher payments on Part D drugs reduced what Caremark owed the pharmacies for underpayments on commercial drugs when the accounts were reconciled. Those offsets gave Caremark a financial benefit that the Medicare reports failed to reflect.

The reporting rule had changed in 2010. Part D drug costs had to reflect the price ultimately received by the pharmacy, with the PBM’s spread treated as an administrative cost. The court found that the offsets belonged in the price-concession reporting even though no separate refund check came back from the pharmacy.

An Aetna Medicare actuary started asking questions after comparing Aetna’s drug prices with prices available through other Part D sponsors. Caremark initially attributed the higher prices to market conditions. An executive later acknowledged that reducing Aetna’s Part D prices would mean paying more elsewhere. The actuary recognized the connection to commercial pricing and brought the whistleblower case.

An outside audit had confirmed that Aetna’s point-of-sale prices matched Caremark’s pharmacy payments. But that audit excluded direct and indirect remuneration reporting, where the year-end concessions belonged. The court gave little weight to a separate review that relied on Caremark’s representations without independently checking the contracts and reconciliation spreadsheets.

We see little comfort in an audit that checks the pharmacy payment but leaves the year-end concessions out. The reassuring answer depended on the narrower question.

Elixir’s Settlement Over Rebates Reported as Service Fees

Rite Aid and Elixir Insurance agreed to $101 million in fixed settlement payments over allegedly false Medicare rebate reporting. The settlement announced on July 10, 2024 concerned a Part D sponsor and the PBMs supplying its rebate information. Elixir Insurance offered the drug plans. Rx Options and Rx Solutions handled pharmacy benefit management.

The government alleged that retained manufacturer rebates appeared in Elixir Insurance’s annual reports as bona fide service fees, although manufacturers had not negotiated to pay those fees. The agreement identifies the retention formulas: 20% of estimated manufacturer rebates from 2014 through 2019, followed by 5.5% of wholesale acquisition cost for rebateable drugs in 2020.

The whistleblower’s complaint calls the rebate-retaining business EPS and alleges that it performed no services in exchange:

The allegation goes beyond the accounting label to the work supposedly purchased. What service did the manufacturer agree to buy, who performed it, and how did the retained payment reach the sponsor’s report?

A former Rx Options employee brought the case, and the government joined it. The Department of Health and Human Services’ inspector general and the FBI’s Cleveland office provided substantial investigative assistance.

Medco’s Preferred Drug and Discounted Drugs Were Different

Medco agreed to a $7.9 million settlement on May 20, 2015 over alleged kickbacks connected to Nexium’s formulary position. The government said Medco sought compensation from AstraZeneca for making Nexium the sole and exclusive proton pump inhibitor on certain formularies. Some or all of that compensation allegedly arrived as reduced prices on Prilosec, Toprol XL and Plendil.

The alleged bargain: favor one drug, discount others. Looking only at Nexium’s rebate account would miss the transaction the government described.

The affected program was Medicare’s Retiree Drug Subsidy program. Former AstraZeneca employees brought the whistleblower case, showing why manufacturer-side knowledge can expose a PBM arrangement. AstraZeneca reached its own separate resolution over the same conduct.

RxAmerica’s Plan Finder Prices and Claims Told Different Stories

RxAmerica agreed to pay $5.25 million in an October 15, 2012 False Claims Act settlement. The government alleged that the company submitted false prices for certain generic drugs to Medicare’s Plan Finder during 2007 and 2008, despite certifying that its information would be accurate.

Plan Finder helped beneficiaries compare expected out-of-pocket costs before choosing a drug plan. The government alleged that RxAmerica then received Part D payments on covered claims at prices sometimes significantly higher than those submitted for the comparison tool. The same announcement described a separate $5 million Federal Trade Commission agreement to compensate beneficiaries.

State Medicaid Settlements Follow the Costs Reported to the State

Centene’s California settlement concerned allegedly inflated prescription costs reported by California Health & Wellness and Health Net to Medi-Cal. California’s attorney general announced the $215,392,758 settlement on February 8, 2023, describing it as twice the value of the alleged inflated price reporting.

The state alleged that Centene obtained discounted fees through its PBM contracts but failed to disclose or pass those savings to Medi-Cal. The challenged reporting covered January 2017 through December 2018. California’s Department of Justice investigated with assistance from the Department of Health Care Services.

The useful comparison is between the managed care plans’ reported costs and the discounted costs behind them. For a contracting or finance insider, the savings negotiated upstream and the expense reported downstream may be visible in different systems.

OPM’s Compass Rose Audit Turned on the Pass-Through Promise

The Office of Personnel Management’s inspector general questioned $18,443,118, including lost investment income, in its November 14, 2024 Compass Rose audit. The audit examined Express Scripts’ administration of the plan’s Federal Employees Health Benefits pharmacy operations for 2017 through 2022. Its findings called for contract corrections and repayments.

The disputed retail-pricing question was specific. Auditors said the plan should receive the value of discounts negotiated in Express Scripts’ pharmacy network agreements. They found that Express Scripts used internal prices that varied among clients while satisfying the overall discount across its business.

Compass Rose disagreed with the retail finding. It said the plan paid what Express Scripts paid the pharmacies, and that its negotiated pricing reflected the networks the plan had selected. The inspector general answered that the contract required the value of the negotiated network discounts.

The audit also examined pharmacy transaction credits, purchasing discounts at Express Scripts’ own mail-order and specialty pharmacies, and manufacturer rebates handled by Ascent Health Services. For the Ascent finding, auditors compared manufacturer agreements with what reached Compass Rose. They attributed the shortfall to lower rebate percentages agreed internally between Express Scripts and Ascent.

The report records a credit for the rebate principal, and Compass Rose reported that the money had returned to the federal program. Auditors recommended verifying that the credit fully reached the program. Cigna’s response maintained that Express Scripts had complied with the agreement and had agreed to the credit to resolve the dispute. Calling the credit voluntary does not answer why the rebate stopped short of the plan.

The connection to Caremark is the pricing reconciliation: a pharmacy payment can match the plan’s charge while the year-end contract calculation tells another story. Here, the inspector general and carrier disputed the contract’s reach. In Caremark, a court decided the reporting claim.

Federal Trade Commission Proceedings Address Competition and Commercial Terms

The Federal Trade Commission’s insulin proceeding concerns Caremark, Express Scripts and OptumRx alongside rebate-negotiating businesses. The agency’s revised complaint identifies Zinc, Ascent and Emisar as manufacturer-rebate negotiators. Express Scripts co-owns Ascent, CVS co-owns Zinc, and Emisar is an indirect UnitedHealth subsidiary. These businesses negotiate manufacturer rebates for PBM clients, putting the receipts inside the same corporate groups whose plans and pharmacies also handle the prescriptions.

The February 2026 Express Scripts notice and August 2026 Caremark/Zinc notice published proposed consent agreements for comment. The Caremark proposal’s member definition excludes Medicare, Medicaid and Exchange plans. Its rebate definition also excludes specified manufacturer administrative and data fees.

Private litigation by benefit plans brings another set of disputes with PBMs. A private plan’s dispute and a whistleblower’s qui tam case have different beneficiaries: the latter seeks recovery on the government’s behalf.

Contract Performance Can Be Hidden in Prescription Records

Medco agreed to pay $137,500,000 in its 2006 consolidated mail-order settlement. The government alleged that, from 1995 through 2004, Medco manipulated prescription receipt dates through cancellations, destruction or reentry, and fabricated records of physician contacts.

The identified contracts served federal employees and TRICARE beneficiaries. Daily turnaround reports, monthly invoices and annual statements could misrepresent performance under those contracts. The alleged receipt-date manipulation matters because it changes the apparent time between an order’s arrival and its handling.

For someone who knows the mail-order workflow, a newly entered prescription can have an older history. The original order and the performance report may tell different stories about whether the promised service happened. The Justice Department announced $23 million for the whistleblowers in the combined cases.

What PBM Whistleblowers Can Explain

The people behind these cases saw different parts of the business. An actuary compared prices. Manufacturer employees knew the consideration behind formulary placement. A PBM employee challenged how rebates were classified. The useful knowledge connected a business decision to a representation and the government payment it affected.

We look at those connections with you: the contract the business used, the amount it received or paid, the report it sent and who understood the difference. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Numbers Differ

If you know why a rebate became a fee, why a pharmacy discount disappeared from a plan report or why an audit missed the adjustment, speak to one of our PBM fraud whistleblower experts about why the numbers differ. We turn that knowledge into a focused case strategy, bring in whistleblower lawyers who understand PBM pricing and government health care payments, and stay beside you through the decisions ahead.